Is CRVS or ZNTL more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Is CGEM or ZNTL more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Does the media favor ZNTL or WVE?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. WAVE Life Sciences' average media sentiment score of 1.14 beat Zentalis Pharmaceuticals' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZNTL or MGTX?

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. MeiraGTx's average media sentiment score of 1.42 beat Zentalis Pharmaceuticals' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XNCR or ZNTL?

In the previous week, Xencor and Xencor both had 1 articles in the media. Xencor's average media sentiment score of 0.75 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zentalis Pharmaceuticals (ZNTL) Competitors

$4.46 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.56 +0.10 (+2.24%)

As of 07/2/2026 05:43 PM Eastern

Compare

ZNTL vs. CRVS, CGEM, WVE, MGTX, and XNCR

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? MarketBeat compares Zentalis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zentalis Pharmaceuticals include Corvus Pharmaceuticals (CRVS), Cullinan Therapeutics (CGEM), WAVE Life Sciences (WVE), MeiraGTx (MGTX), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A

Corvus Pharmaceuticals currently has a consensus price target of $33.33, indicating a potential upside of 118.87%. Zentalis Pharmaceuticals has a consensus price target of $5.83, indicating a potential upside of 30.79%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Corvus Pharmaceuticals has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Corvus Pharmaceuticals	Neutral
Zentalis Pharmaceuticals	Neutral

Corvus Pharmaceuticals' return on equity of -38.92% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Corvus Pharmaceuticals beats Zentalis Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 1 mentions for Zentalis Pharmaceuticals and 0 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.00 equaled Zentalis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cullinan Therapeutics	Neutral
Zentalis Pharmaceuticals	Neutral

Cullinan Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 81.51%. Zentalis Pharmaceuticals has a consensus price target of $5.83, suggesting a potential upside of 30.79%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cullinan Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Cullinan Therapeutics' return on equity of -51.45% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Zentalis Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A

Summary

Zentalis Pharmaceuticals beats Cullinan Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to WAVE Life Sciences?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

89.7% of WAVE Life Sciences shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A
WAVE Life Sciences	$42.73M	28.19	-$204.38M	-$1.06	N/A

Zentalis Pharmaceuticals presently has a consensus target price of $5.83, suggesting a potential upside of 30.79%. WAVE Life Sciences has a consensus target price of $26.41, suggesting a potential upside of 321.91%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.29, suggesting that its stock price is 229% less volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. WAVE Life Sciences' average media sentiment score of 1.14 beat Zentalis Pharmaceuticals' score of 0.00 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Zentalis Pharmaceuticals' return on equity of -53.61% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

Summary

WAVE Life Sciences beats Zentalis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to MeiraGTx?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

MeiraGTx has higher revenue and earnings than Zentalis Pharmaceuticals. MeiraGTx is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A
MeiraGTx	$81.39M	15.84	-$114.20M	-$1.48	N/A

Zentalis Pharmaceuticals presently has a consensus target price of $5.83, suggesting a potential upside of 30.79%. MeiraGTx has a consensus target price of $25.83, suggesting a potential upside of 85.58%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Zentalis Pharmaceuticals and Zentalis Pharmaceuticals both had 1 articles in the media. MeiraGTx's average media sentiment score of 1.42 beat Zentalis Pharmaceuticals' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
MeiraGTx	-151.12%	N/A	-54.96%

67.5% of MeiraGTx shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MeiraGTx beats Zentalis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Xencor?

Xencor (NASDAQ:XNCR) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Xencor has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Xencor has higher revenue and earnings than Zentalis Pharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.86	-$91.92M	-$2.29	N/A
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A

Xencor currently has a consensus target price of $24.50, suggesting a potential upside of 63.33%. Zentalis Pharmaceuticals has a consensus target price of $5.83, suggesting a potential upside of 30.79%. Given Xencor's stronger consensus rating and higher possible upside, research analysts plainly believe Xencor is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Xencor and Xencor both had 1 articles in the media. Xencor's average media sentiment score of 0.75 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xencor beats Zentalis Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$317.49M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-2.58	21.61	28.02	24.70
Price / Sales	4.71	325.99	534.82	99.70
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.49	8.66	10.96	6.46
Net Income	-$137.06M	$23.81M	$3.57B	$337.01M
7 Day Performance	10.40%	3.39%	2.12%	1.69%
1 Month Performance	21.86%	10.81%	5.25%	3.81%
1 Year Performance	256.80%	62.61%	33.29%	23.90%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	2.0376 of 5 stars	$4.46 flat	$5.83 +30.8%	+256.8%	$317.49M	$67.43M	N/A	160
CRVS Corvus Pharmaceuticals	2.157 of 5 stars	$14.48 +7.3%	$33.33 +130.2%	+287.0%	$1.13B	N/A	N/A	30	Positive News
CGEM Cullinan Therapeutics	2.2553 of 5 stars	$18.42 +0.1%	$32.00 +73.7%	+125.7%	$1.13B	N/A	N/A	30
WVE WAVE Life Sciences	3.415 of 5 stars	$5.68 -2.6%	$26.41 +365.0%	-10.2%	$1.12B	$42.73M	N/A	240	Positive News Gap Down
MGTX MeiraGTx	2.7864 of 5 stars	$12.54 +3.6%	$25.83 +106.0%	+85.5%	$1.12B	$81.39M	N/A	300	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. CRVS, CGEM, WVE, MGTX, and XNCR

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Summary

How does Zentalis Pharmaceuticals compare to Cullinan Therapeutics?

Summary

How does Zentalis Pharmaceuticals compare to WAVE Life Sciences?

Summary

How does Zentalis Pharmaceuticals compare to MeiraGTx?

Summary

How does Zentalis Pharmaceuticals compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. CRVS, CGEM, WVE, MGTX, and XNCR

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Which has better earnings & valuation, CRVS or ZNTL?

Do analysts prefer CRVS or ZNTL?

Which has more volatility and risk, CRVS or ZNTL?

Does the media favor CRVS or ZNTL?

Is CRVS or ZNTL more profitable?

Do institutionals and insiders hold more shares of CRVS or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Cullinan Therapeutics?

Does the media prefer CGEM or ZNTL?

Do analysts rate CGEM or ZNTL?

Is CGEM or ZNTL more profitable?

Do insiders and institutionals hold more shares of CGEM or ZNTL?

Which has more risk & volatility, CGEM or ZNTL?

Which has preferable valuation and earnings, CGEM or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to WAVE Life Sciences?

Do institutionals and insiders have more ownership in ZNTL or WVE?

Which has higher valuation & earnings, ZNTL or WVE?

Do analysts prefer ZNTL or WVE?

Which has more risk & volatility, ZNTL or WVE?

Does the media favor ZNTL or WVE?

Is ZNTL or WVE more profitable?

Summary

How does Zentalis Pharmaceuticals compare to MeiraGTx?

Which has preferable earnings and valuation, ZNTL or MGTX?

Do analysts recommend ZNTL or MGTX?

Does the media favor ZNTL or MGTX?

Which has more risk & volatility, ZNTL or MGTX?

Is ZNTL or MGTX more profitable?

Do institutionals & insiders hold more shares of ZNTL or MGTX?

Summary

How does Zentalis Pharmaceuticals compare to Xencor?

Which has more risk & volatility, XNCR or ZNTL?

Is XNCR or ZNTL more profitable?

Which has stronger valuation & earnings, XNCR or ZNTL?

Do analysts recommend XNCR or ZNTL?

Does the media refer more to XNCR or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools